MICHELLE GIDDINGS: Open Payments
NPI 1336303072 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$61,786 in 225 payments from 15 companies in 2025. Trend: 2023 $24,884 · 2024 $27,520 · 2025 $61,786
Speaker / faculty: $30,126Travel & lodging: $10,036Honoraria: $9,425Consulting: $6,480Food & beverage: $5,610Education: $109
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 62 | $36,105 |
| Otsuka America Pharmaceutical, Inc. | 41 | $12,338 |
| Axsome Therapeutics, Inc. | 26 | $11,155 |
| Teva Pharmaceuticals USA, Inc. | 19 | $466 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $363 |
| Neurocrine BioSciences, Inc. | 15 | $301 |
| Lundbeck LLC | 9 | $245 |
| Alkermes, Inc. | 8 | $211 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $146 |
| ABBVIE INC. | 11 | $140 |
Products named: COBENFY, REXULTI, Auvelity, CAPLYTA, INGREZZA, AUSTEDO XR, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across NV — which companies pay providers there.
